Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9Y399

UPID:
RT02_HUMAN

ALTERNATIVE NAMES:
28S ribosomal protein S2, mitochondrial

ALTERNATIVE UPACC:
Q9Y399; Q5T899; Q9BSQ4

BACKGROUND:
The protein Small ribosomal subunit protein uS2m, alternatively named 28S ribosomal protein S2, mitochondrial, is indispensable for mitochondrial translation and the assembly and stability of the mitoribosome. Its function underscores the intricate relationship between ribosomal proteins and mitochondrial energy production.

THERAPEUTIC SIGNIFICANCE:
The association of Small ribosomal subunit protein uS2m with Combined oxidative phosphorylation deficiency 36 underscores its therapeutic potential. Exploring the function of Small ribosomal subunit protein uS2m could lead to novel therapeutic approaches for mitochondrial diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.